Evidence map›Paper›PMID 32964197›Full record

ArticleJournal of the American College of Clinical Pharmacy : JACCP2020

Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service.

Idaliz Rodríguez-Escudero, Julio A Cedeño, Ileana Rodríguez-Nazario, Gledys Reynaldo-Fernández, Leyanis Rodríguez-Vera, Niretzy Morales, Braulio Jiménez-Vélez, Gualberto Ruaño, Jorge Duconge

Open access · greenAbstract read
In one paragraph

Article in Journal of the American College of Clinical Pharmacy : JACCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Idaliz Rodríguez-EscuderoSchool of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Julio A CedeñoSchool of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Ileana Rodríguez-NazarioSchool of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
Gledys Reynaldo-FernándezInstitute of Pharmacy and Foods, University of Havana, Cuba.
Leyanis Rodríguez-VeraInstitute of Pharmacy and Foods, University of Havana, Cuba.
Niretzy MoralesClínica de Servicios Psicológicos, Toa Baja, Puerto Rico.
Braulio Jiménez-VélezDepartment of Biochemistry, University of Puerto Rico, Medical Sciences Campus, School of Medicine, San Juan, Puerto Rico.
Gualberto RuañoInstitute of Living at Hartford Hospital, Laboratory of Personalized Health, Genomas, Inc., Hartford, Connecticut.
Jorge DucongeSchool of Pharmacy, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.ORCID 0000-0002-5955-3449
University of Puerto Rico, Medical Sciences Campus · PRUniversity of Havana · CUHartford Hospital · US

Funding

Upstream Regulation and Downstream effectors of c-MYC in Ovarian CancerU54MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Carmen M Velez Vega · 2017 to 2026
$35.8M
NIMHD NIH HHS U54 MD007600
6 · The paper itself

Abstract

introductionPharmacists are poised to be the health care professionals best suited to provide medication-related consults and services based on a patient's genetics. Despite its potential benefits, the implementation of pharmacogenetic (PGx) testing into primary clinical settings has been slow among medically underserved populations. To our knowledge, this is the first time that PGx-driven recommendations have been incorporated into a Comprehensive Medication Management (CMM) service in a Hispanic population.

objectivesThe aim of this study is to evaluate the clinical utility of adding PGx guidance into pharmacist-driven CMM.

methodsThis is a pre- and post-interventional design study. Patients were recruited from a psychologist's clinic. A total of 24 patients had a face-to-face interview with a pharmacist to complete a CMM, Personal Medication Record, and Medication-Related Action Plan (MAP) blind to PGx findings. Collected buccal DNA samples were genotyped using drug-metabolizing enzymes and transporters (DMET) Plus Array.

resultsThe pharmacist generated new MAPs for each patient based on PGx results. Genetic variants that could potentially affect the safety and effectiveness of at least one drug in the pharmacotherapy were identified in 96% of patients, for whom the pharmacist changed the initial recommendations. Polymorphisms in genes encoding for isoenzymes CYP2D6, CYP2C19, and CYP2C9 were identified in 83%, 52%, and 41% of patients, respectively. Pharmacists performing CMM identified 22 additional medication problems after PGx determinations. Moreover, they agreed with the clinical utility of PGx in the studied sample based on perceived value of adding PGx to traditional CMM and its utility in the decision-making process of pharmacists.

conclusionsThe study confirmed the critical role to be played by pharmacists in facilitating the clinical usage of relevant genetic information to optimize drug therapy decisions as well as their involvement on many levels of these multidisciplinary implementation efforts, including championing and leading PGx-guided CMM services.

Indexed as

clinical decision supportcytochrome P450pharmacogenetics

Identifiers

PMID32964197
PMCPMC7505210
OpenAlexW3022566593

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.